Nucleic acids encoding targeted therapeutic lysosomal enzyme fusion proteins
US10301369B2 · kind B2 · utility
4Cited by
6References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 28, 2017 |
| Grant date | May 28, 2019 |
| Priority date | — |
| Expiry date | Aug 28, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.